Chromocell Therapeutics Corporation (CHRO) — Cash Flow-to-Debt Ratio
Latest as of June 2025:
-0.06x
Chromocell Therapeutics Corporation (CHRO) has a Cash Flow-to-Debt Ratio of -0.06x as of June 2025, meaning its operating cash flow of $-447.14K could theoretically repay 0% of its total liabilities ($7.32 Million) in one year. See CHRO financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.06x
Operating CF / Total Liabilities
Operating Cash Flow
$-447.14K
USD
Total Liabilities
$7.32 Million
USD
Data as of
Jun 2025
Most recent filing
Chromocell Therapeutics Corporation Cash Flow-to-Debt Ratio (2020–2024)
Historical debt coverage capacity for Chromocell Therapeutics Corporation across 9 annual periods. For the full cash flow conversion analysis, see how efficiently does Chromocell Therapeutics Corporation generate cash.
Annual Cash Flow-to-Debt Ratio for Chromocell Therapeutics Corporation (2020–2024)
Year-by-year debt coverage analysis for Chromocell Therapeutics Corporation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.42x | $-5.79 Million | $4.08 Million | ▼ -845.8% |
| 2023 | -0.15x | $-981.03K | $6.54 Million | ▲ +0.0% |
| 2023 | -0.15x | $-981.03K | $6.54 Million | ▲ +64.0% |
| 2022 | -0.42x | $-1.57 Million | $3.76 Million | ▲ +0.0% |
| 2022 | -0.42x | $-1.57 Million | $3.76 Million | ▲ +3.8% |
| 2021 | -0.43x | $-1.59 Million | $3.68 Million | ▲ +0.0% |
| 2021 | -0.43x | $-1.59 Million | $3.68 Million | ▲ +56.4% |
| 2020 | -0.99x | $-3.63 Million | $3.65 Million | ▲ +0.0% |
| 2020 | -0.99x | $-3.63 Million | $3.65 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.